Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ZJYL · Nasdaq · United States · Orthopedic, Prosthetic & Surgical Appliances & Supplies
In shortJin Medical International Ltd. is profitable, burns cash and holds more cash than debt, with revenue shrinking (−12.0% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 2.9% | 26/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 5.8% | 43/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 4.1% | 20/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 1.1% | 7/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.86× | 88/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.64× | 76/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 5.16 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -18.0% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | -3.13× | 0/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 4 | 17/100 |
| Revenue growth volatility | 13.6% | 61/100 |
| Operating margin volatility | 5.0% | 64/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.5% | 31/100 |
|---|---|---|
| EPS growth, 3-year average | -20.6% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 21 | 19 | 20 | 24 | 21 |
| Cost of revenue | 14 | 13 | 13 | 14 | 15 |
| Gross profit | 6.4 | 6.2 | 6.8 | 9.5 | 6 |
| Research & development | 1.6 | 1.9 | 1.5 | 1.5 | 1.6 |
| Operating income | 2.6 | 2.1 | 2.9 | 3.6 | 0.6 |
| Pre-tax income | 2.9 | 2.7 | 3.2 | 4.2 | 1.6 |
| Income tax | 0.2 | 0 | 0.3 | 0.8 | 0.2 |
| Net income | 2.6 | 2.7 | 2.9 | 3.7 | 1.2 |
| Diluted EPS | $0.02 | $0.02 | $0.02 | $0.02 | $0.01 |
| Diluted shares (millions) | 135 | 135 | 145 | 156 | 157 |
5.16 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Sep 30, 2025 · Data updated Feb 10, 2026